314 related articles for article (PubMed ID: 32164494)
1. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
Guthrie R
Postgrad Med; 2020 May; 132(4):314-319. PubMed ID: 32164494
[TBL] [Abstract][Full Text] [Related]
2. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; von Eynatten M; George JT; Johansen OE; Wanner C;
Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
[TBL] [Abstract][Full Text] [Related]
3. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Marx N; Kolkailah AA; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto RD; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK
JAMA Cardiol; 2024 Feb; 9(2):134-143. PubMed ID: 38170502
[TBL] [Abstract][Full Text] [Related]
4. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
McGuire DK; Alexander JH; Johansen OE; Perkovic V; Rosenstock J; Cooper ME; Wanner C; Kahn SE; Toto RD; Zinman B; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; Marx N;
Circulation; 2019 Jan; 139(3):351-361. PubMed ID: 30586723
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial.
Cooper ME; Rosenstock J; Kadowaki T; Seino Y; Wanner C; Schnaidt S; Clark D; Johansen OE;
Diabetes Obes Metab; 2020 Jul; 22(7):1062-1073. PubMed ID: 32037653
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
Hanssen NM; Jandeleit-Dahm KA
Diab Vasc Dis Res; 2019 Jul; 16(4):303-309. PubMed ID: 31018682
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
Rosenstock J; Marx N; Neubacher D; Seck T; Patel S; Woerle HJ; Johansen OE
Cardiovasc Diabetol; 2015 May; 14():57. PubMed ID: 25990013
[TBL] [Abstract][Full Text] [Related]
10. Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.
Biessels GJ; Verhagen C; Janssen J; van den Berg E; Zinman B; Rosenstock J; George JT; Passera A; Schnaidt S; Johansen OE;
Diabetes Care; 2019 Oct; 42(10):1930-1938. PubMed ID: 31399442
[TBL] [Abstract][Full Text] [Related]
11. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA
Inagaki N; Yang W; Watada H; Ji L; Schnaidt S; Pfarr E; Okamura T; Johansen OE; George JT; von Eynatten M; Rosenstock J; Perkovic V; Wanner C; Cooper ME; Alexander JH; Komuro I; Nangaku M
Diabetol Int; 2020 Apr; 11(2):129-141. PubMed ID: 32206483
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA.
Ghosh S; Mukhopadhyay P; Pandey P; Chatterjee P; Pandit K
Diab Vasc Dis Res; 2020; 17(6):1479164120973653. PubMed ID: 33213193
[TBL] [Abstract][Full Text] [Related]
15. Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial.
Kadowaki T; Wang G; Rosenstock J; Yabe D; Peng Y; Kanasaki K; Mu Y; Mattheus M; Keller A; Okamura T; Johansen OE; Marx N
Diabetol Int; 2021 Jan; 12(1):87-100. PubMed ID: 33479584
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
[TBL] [Abstract][Full Text] [Related]
17. Safety of Linagliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
Aljohani H; Alrubaish FS; Alghamdi WM; Al-Harbi F
Ther Innov Regul Sci; 2024 Jul; 58(4):622-633. PubMed ID: 38634983
[TBL] [Abstract][Full Text] [Related]
18. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.
Patorno E; Gopalakrishnan C; Brodovicz KG; Meyers A; Bartels DB; Liu J; Kulldorff M; Schneeweiss S
Diabetes Obes Metab; 2019 Aug; 21(8):1824-1836. PubMed ID: 30941884
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
Li YR; Tsai SS; Chen DY; Chen ST; Sun JH; Chang HY; Liou MJ; Chen TH
Cardiovasc Diabetol; 2018 Jan; 17(1):2. PubMed ID: 29301579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
